[go: up one dir, main page]

CO5140117A1 - Derivados terapeuticos de benzamida - Google Patents

Derivados terapeuticos de benzamida

Info

Publication number
CO5140117A1
CO5140117A1 CO99075519A CO99075519A CO5140117A1 CO 5140117 A1 CO5140117 A1 CO 5140117A1 CO 99075519 A CO99075519 A CO 99075519A CO 99075519 A CO99075519 A CO 99075519A CO 5140117 A1 CO5140117 A1 CO 5140117A1
Authority
CO
Colombia
Prior art keywords
ring
radicals
independently selected
6alkylene
alkoxy
Prior art date
Application number
CO99075519A
Other languages
English (en)
Inventor
Alain Claude-Marie Daugan
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of CO5140117A1 publication Critical patent/CO5140117A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/335—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/42—Radicals substituted by singly-bound nitrogen atoms having hetero atoms attached to the substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/20—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D233/24—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/12—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/28—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/10—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/14—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

Un compuesto de fórmula (I)<EMI FILE="99075519_1" ID="1" IMF=JPEG >en dondeA representa N ó CH;X se selecciona de los siguientes grupos:(i) -C1-6alquileno-, opcionalmente conteniendo uno o dos enlaces dobles y opcionalmente substituido por uno o más grupos hidroxi, alquilo, C1-6, alcoxi C1-6, acilo C1-6 o aciloxi C1-6,(ii) oxo, sulfonilo, tioxo,(iii) -C1-6alquilencarbonilo-, -C1-6alquilensulfonilo-,-C1-6alquilentioxo,(iv) -C2-6alquilenoxi, -C2-6alquilentio-, C2-6alquilen(N-H ó N-C1-6alquil)amino-,(v) -C1-6alquilencarboxi-, -C1-6alquilentioamido-, -C1-6alquilen(N-H ó N-C1-6alquil)carboxiamido-, y(vi) -C2-6alquilenoxicarbonil-, -C2-6alquilentiocarbonil-,-C2-6 alquilen(N-H ó N-C1-6alquil)aminocarbonilo-;Z representa un enlace directo o -C1-6alquileno-, opcionalmente conteniendo un enlace doble y opcionalmente substituido por uno o más grupos hidroxi, alquilo C1-6, alcoxi C1-6, acilo C1-6 o aciloxi C1-6;R1 se selecciona de los siguientes grupos:(i) hidrógeno, C1-3 perfluoroalquilo,(ii) arilo C6-10, cicloalquilo C3-8 y derivados benzo de fusión de los mismos, policicloalquilo C7-10, cicloalquenilo C4-8, policicloalquenilo C7-10,(iii) un heterociclilo del grupo que consiste de radicales monocíclicos y radicales policíclicos fundidos, en donde los radicales contienen un total de 5-14 átomos en el anillo, en donde los radicales contienen un total de 1-4 heteroátomos en el anillo independientemente seleccionados de oxígeno, nitrógeno y azufre, y en donde los anillos individuales de los radicales pueden ser independientemente saturados, parcialmente insaturados o aromáticos y (iv) en donde X es alquileno C1-6 y Z es un enlace directo, o Z es alquileno C1-6, R1 puede representar adicionalmente un grupo halógeno, ciano, nitro o acilo C1-6,en donde cuando R1 contiene uno o más anillos, los anillos pueden cada uno independientemente soportar de 0 a 4 substituyentes independientemente seleccionados de(i) halógeno, hidroxi, ciano, nitro, formilo, alquilsulfonilamino -C1-6,- 2 - (ii) alquilo C1-6, cicloalquilo C3-8, perfluoroalquilo C1-3,(iii) alcoxi C1-6, metilendioxi, perfluoroalcoxi C1-3, alquiltio C1-6,(iv) amino, alquilamino C1-6, dialquilamino C1-6,(v) fenilo, fenoxi, feniltio, halofeniltio, bencilo, benciloxi,(vi) hidroxicarbonilo, C1-6alcoxicarbonilo,(vii) aminocarbonilo, alquilaminocarbonilo C1-6, dialquilaminocarbonilo C1-6, dialquilaminocarbonilo C1-6 aIcoxi C1-6, perfluoroalquilaminocarbonilo C1-3,(viii) acilo C1-6, aciloxi C1-6, aciloxi C1-6 alquilo C1-6, acilamino C1-6, y(ix) un heterociclilo aromático que consiste de radicales monocíclicos en donde los radicales contienen de 5-6 átomos en el anillo, en donde los radicales contienen un total de 1-4 heteroátomos en el anillo independientemente seleccionados de oxígeno, nitrógeno y azufre, y en donde cada uno de los grupos heterociclilo está opcionalmente substituido por uno o más grupos seleccionados independientemente de halógeno, alquilo C1-4, alcoxi C1-4, perfluoroalquilo C1-3, y perfluoroalcoxi C1-3;Y representa una ligadura oxi o directa, -alquileno C1-6-, -oxialquilenoC1-6, o un heterociclilo consistente de radicales monocíclicos, en donde los radicales contienen 5 átomos en el anillo, y en donde los radicales contienen un total de 1-4 heteroátomos en el anillo seleccionados independientemente de oxígeno, nitrógeno y azufre, y en donde el anillo puede estar independientemente saturado, parcialmente insaturado o aromático;R2 representa fenilo, cicloalquilo C3-8 o heterociclilo consistente de radicales monocíclicos en donde los radicales contienen un total de 5-6 átomos en el anillo, en donde los radicales contienen un total de1-4 heteroátomos en el anillo independientemente seleccionados de oxígeno, nitrógeno y azufre, en donde el anillo puede ser independientemente saturado, parcialmente insaturado o aromático; y en donde cada R2 está opcionalmente substituido por uno o más grupos independientemente seleccionados de halógeno, alquilo C1-4, alcoxi C1-4, cicloalquilo C3-8, perfluoroalquilo C1-3, perfluoroalcoxi C1-3, hidroxicarbonilo, alcoxicarbonilo C1-6, ciano, nitro, alquilaminosulfonilo;R3 representa hidrógeno o uno o más grupos seleccionados independientemente de halógeno, alquilo C1-4, alcoxi C1-4, perfluoroalquilo C1-3, o perfluoroalcoxi C1 -3; o una sal fisiológicamente aceptable, solvato o derivado de la misma.
CO99075519A 1998-12-03 1999-12-01 Derivados terapeuticos de benzamida CO5140117A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9826412.0A GB9826412D0 (en) 1998-12-03 1998-12-03 Chemical compounds

Publications (1)

Publication Number Publication Date
CO5140117A1 true CO5140117A1 (es) 2002-03-22

Family

ID=10843463

Family Applications (1)

Application Number Title Priority Date Filing Date
CO99075519A CO5140117A1 (es) 1998-12-03 1999-12-01 Derivados terapeuticos de benzamida

Country Status (22)

Country Link
US (1) US6552022B1 (es)
EP (1) EP1135378A1 (es)
JP (1) JP2002531444A (es)
KR (1) KR20010081112A (es)
CN (1) CN1131222C (es)
AR (1) AR021434A1 (es)
AU (1) AU750259B2 (es)
BR (1) BR9915895A (es)
CA (1) CA2353394A1 (es)
CO (1) CO5140117A1 (es)
CZ (1) CZ20011973A3 (es)
GB (1) GB9826412D0 (es)
HU (1) HUP0104497A3 (es)
IL (1) IL142913A0 (es)
NO (1) NO20012688L (es)
NZ (1) NZ511481A (es)
PE (1) PE20001562A1 (es)
PL (1) PL348042A1 (es)
TR (1) TR200101513T2 (es)
TW (1) TW515796B (es)
WO (1) WO2000032582A1 (es)
ZA (1) ZA200103680B (es)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6197798B1 (en) 1998-07-21 2001-03-06 Novartis Ag Amino-benzocycloalkane derivatives
AU6824700A (en) * 1999-07-20 2001-02-05 Novartis Ag Organic compounds
EP1259484B1 (en) * 2000-01-18 2005-05-18 Novartis AG Carboxamides useful as inhibitors of microsomal triglyceride transfer protein and of apolipoprotein b secretion
GB0013346D0 (en) * 2000-06-01 2000-07-26 Glaxo Group Ltd Therapeutic benzamide derivatives
GB0013378D0 (en) * 2000-06-01 2000-07-26 Glaxo Group Ltd Use of therapeutic benzamide derivatives
GB0013383D0 (en) * 2000-06-01 2000-07-26 Glaxo Group Ltd Therapeutic benzamide derivatives
JO2654B1 (en) 2000-09-04 2012-06-17 شركة جانسين فارماسوتيكا ان. في Multiple aryl caroxa amides are useful as lipid - lowering agents
CN1478077A (zh) * 2000-10-05 2004-02-25 ����ҩƷ��ҵ��ʽ���� 作为apo b分泌抑制剂的苯甲酰胺化合物
JO2409B1 (en) 2000-11-21 2007-06-17 شركة جانسين فارماسوتيكا ان. في Second-phenyl carboxy amides are useful as lipid-lowering agents
DE10101150A1 (de) 2001-01-12 2002-07-18 Bayer Ag Verfahren zur Herstellung trifluormethyl-substituierter Biphenylcarbonsäuren und neue trichlormethyl-und trifluormethyl-substituierte Biphenylcarbonitrile
US20040072865A1 (en) * 2001-01-15 2004-04-15 Bouillot Anne Marie Jeanne Aryl piperidine derivatives as inducers of ldl-receptor expression
US20040077654A1 (en) * 2001-01-15 2004-04-22 Bouillot Anne Marie Jeanne Aryl piperidine and piperazine derivatives as inducers of ldl-receptor expression
EP1351937A1 (en) * 2001-01-15 2003-10-15 Glaxo Group Limited Aryl piperidine derivatives as inducers of ldl-receptor expression
JO2390B1 (en) * 2001-04-06 2007-06-17 شركة جانسين فارماسوتيكا ان. في Diphenylcarboxamides act as lipid-lowering agents
GB0109287D0 (en) * 2001-04-12 2001-05-30 Glaxo Group Ltd Therapeutic benzamide derivatives
EP1935885A3 (en) * 2001-05-22 2008-10-15 Neurogen Corporation Melanin concentrating hormone receptor ligands : substituted 1-benzyl-4-aryl piperazine analogues.
CN1703401A (zh) 2001-05-22 2005-11-30 神经原公司 黑色素浓集激素受体的配体:取代的1－苄基－4－芳基哌嗪类似物
WO2002098839A1 (en) * 2001-06-01 2002-12-12 Tanabe Seiyaku Co., Ltd. Biphenylcarboxamides and process for preparation thereof
US6727264B1 (en) 2001-07-05 2004-04-27 Synaptic Pharmaceutical Corporation Substituted anilinic piperidines as MCH selective antagonists
JP2005510564A (ja) * 2001-11-28 2005-04-21 藤沢薬品工業株式会社 アポリポタンパク質ｂ阻害剤としての複素環式アミド化合物
GB0129015D0 (en) * 2001-12-04 2002-01-23 Glaxo Group Ltd Compounds
GB0129013D0 (en) * 2001-12-04 2002-01-23 Glaxo Group Ltd Compounds
RU2293721C2 (ru) 2002-02-28 2007-02-20 Джапан Тобакко Инк. Сложноэфирные соединения и их применение в медицине
UA79300C2 (en) * 2002-08-12 2007-06-11 Janssen Pharmaceutica Nv N-aryl piperidine substituted biphenylcarboxamides as inhibitors of apolipoprotein b secretion
WO2004039795A2 (en) * 2002-10-29 2004-05-13 Fujisawa Pharmaceutical Co., Ltd. Amide compounds for the treatment of hyperlipidemia
WO2005021486A1 (ja) 2003-08-29 2005-03-10 Japan Tobacco Inc. エステル誘導体及びその医薬用途
UA83510C2 (en) * 2003-12-09 2008-07-25 Янссен Фармацевтика Н.В. N-aryl piperidine substituted biphenylcarboxamides as inhibitors of apolipoprotein b
MXPA06010253A (es) 2004-03-10 2007-02-16 Janssen Pharmaceutica Nv Aril piperidinas o piperazinas sustituidas con heterociclos de cinco miembros inhibidoras de la proteina de transferencia microsomal de trigliceridos.
CA2580857A1 (en) 2004-09-20 2006-09-28 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
MX2007003319A (es) 2004-09-20 2007-06-05 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como agentes terapeuticos.
US8071603B2 (en) 2004-09-20 2011-12-06 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors
TW200626138A (en) 2004-09-20 2006-08-01 Xenon Pharmaceuticals Inc Heterocyclic derivatives and their use as therapeutic agents
CN101084212A (zh) 2004-09-20 2007-12-05 泽农医药公司 杂环衍生物及其作为硬脂酰CoA去饱和酶介导剂的用途
MX2007003318A (es) 2004-09-20 2007-05-18 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como agentes terapeuticos.
CA2580855A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
US8101774B2 (en) 2004-10-18 2012-01-24 Japan Tobacco Inc. Ester derivatives and medicinal use thereof
EP2029138A1 (en) 2005-06-03 2009-03-04 Xenon Pharmaceuticals Inc. Aminothiazole derivatives as human stearoyl-coa desaturase inhibitors
GB0521244D0 (en) 2005-10-19 2005-11-30 Astrazeneca Ab Benzamide compounds
WO2007053436A1 (en) * 2005-10-31 2007-05-10 Janssen Pharmaceutica N.V. Substituted piperazines and piperidines as modulators of the neuropeptide y2 receptor
JO2653B1 (en) 2006-10-24 2012-06-17 شركة جانسين فارماسوتيكا ان. في Tetrahydroflavin 1-carboxylic acid substituted with pyridine or pyrazine inhibit MTB
WO2008049808A1 (en) 2006-10-24 2008-05-02 Janssen Pharmaceutica Nv Mtp inhibiting tetrahydro-naphthalene-1-carboxylic acid derivatives
WO2008148851A1 (en) 2007-06-08 2008-12-11 Janssen Pharmaceutica N.V. Piperidine/piperazine derivatives
JO2972B1 (en) * 2007-06-08 2016-03-15 جانسين فارماسوتيكا ان. في Piperidine / piperazine derivatives
PA8783601A1 (es) 2007-06-08 2009-01-23 Janssen Pharmaceutica Nv Derivados de piperidina/piperazina
WO2008148840A1 (en) 2007-06-08 2008-12-11 Janssen Pharmaceutica N.V. Piperidine/piperazine derivatives
PE20140572A1 (es) 2008-06-05 2014-05-16 Janssen Pharmaceutica Nv Combinaciones de drogas que comprenden un inhibidor de dgat y un agonista de ppar
CN102089278A (zh) * 2008-06-11 2011-06-08 Irm责任有限公司 用于治疗疟疾的化合物和组合物
US8981084B2 (en) * 2010-01-13 2015-03-17 Tempero Pharmaceuticals, Inc. Oxadiazole HDAC inhibitors
BR112018015389B1 (pt) 2016-03-17 2023-12-19 F. Hoffmann-La Roche Ag Derivado de 5-etil-4-metil-pirazol-3-carboxamida, seu processo de fabricação, preparação farmacêutica oral e uso
AR109304A1 (es) 2016-08-10 2018-11-21 Sumitomo Chemical Co Compuesto de oxadiazol y su uso

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES291187A1 (es) * 1963-04-04 1964-01-16 American Cyanamid Co Un procedimiento para preparar piperazinas sustituidas
US4022900A (en) * 1970-09-09 1977-05-10 Marion Laboratories, Inc. Compositions containing 1,2,3,4-tetrahydroisoquinolines used as hypotensive agents
GB9119932D0 (en) 1991-09-18 1991-10-30 Glaxo Group Ltd Chemical compounds
GB9119920D0 (en) * 1991-09-18 1991-10-30 Glaxo Group Ltd Chemical compounds
DE69232003T2 (de) * 1991-09-18 2002-04-25 Glaxo Group Ltd., Greenford Benzanilidderivate als 5-HT1D-Antagonisten
WO1996040640A1 (en) * 1995-06-07 1996-12-19 Pfizer Inc. BIPHENYL-2-CARBOXYLIC ACID-TETRAHYDRO-ISOQUINOLIN-6-YL AMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND/OR APOLIPOPROTEIN B (Apo B) SECRETION
EP0944602A1 (en) * 1996-11-27 1999-09-29 Pfizer Inc. Apo b-secretion/mtp inhibitory amides

Also Published As

Publication number Publication date
BR9915895A (pt) 2001-08-21
TR200101513T2 (tr) 2001-10-22
HUP0104497A3 (en) 2002-07-29
PE20001562A1 (es) 2001-01-26
ZA200103680B (en) 2002-06-14
WO2000032582A1 (en) 2000-06-08
TW515796B (en) 2003-01-01
AR021434A1 (es) 2002-07-17
GB9826412D0 (en) 1999-01-27
PL348042A1 (en) 2002-05-06
CN1334808A (zh) 2002-02-06
IL142913A0 (en) 2002-04-21
CN1131222C (zh) 2003-12-17
NO20012688D0 (no) 2001-05-31
KR20010081112A (ko) 2001-08-27
EP1135378A1 (en) 2001-09-26
HUP0104497A2 (hu) 2002-05-29
AU1656600A (en) 2000-06-19
US6552022B1 (en) 2003-04-22
JP2002531444A (ja) 2002-09-24
NO20012688L (no) 2001-05-31
AU750259B2 (en) 2002-07-11
CA2353394A1 (en) 2000-06-08
CZ20011973A3 (cs) 2001-09-12
NZ511481A (en) 2003-11-28

Similar Documents

Publication Publication Date Title
CO5140117A1 (es) Derivados terapeuticos de benzamida
AR036672A1 (es) Derivados de pirrolidinona
ES2213007T3 (es) Derivados de 4,5-diaril-3(2h)-furanona como inhibidores de la ciclooxigenasa-2.
ES2179490T3 (es) Derivados de 1,2,4-triazolo(3,4-a)ftalazina sustituidos como ligandos de gaba alfa 5.
DE69012840D1 (de) Adenosin-Derivate, die eine Aktivität gegen Bluthochdruck haben.
CO5150227A1 (es) Compuestos de triazol y su utilizacion
ES2196806T3 (es) Derivados de fenilurea y de feniltiourea.
CO5590894A2 (es) Derivados de a-(n-sulfonamido)acetamida como inhibidores del peptido b-amiloideo
CY1113138T1 (el) Παραγωγα 10,10-διαλκυλ προστανοϊκου οξεος ως παραγοντες για μειωση ενδο-οφθαλμικης πιεσης
PE20021056A1 (es) Derivados de pirazol
EA200200299A1 (ru) НОВЫЕ α-АМИНОКИСЛОТНЫЕ СУЛЬФОНИЛЬНЫЕ СОЕДИНЕНИЯ, СПОСОБ ИХ ПОЛУЧЕНИЯ И ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ ИХ СОДЕРЖАЩИЕ
CO5560610A2 (es) Derivados de yodobenzopiran-4-ona que tienen actividad fungicida
PE20011047A1 (es) Compuesto de amida y composiciones farmaceuticas para inhibir proteinquinasas
AR033306A1 (es) Compuestos
PE20040458A1 (es) Piridinas sustituidas con actividad anti-angiogenica
UY25987A1 (es) Procedimiento para preparar complejo del inhibidor de ras-fa rnesiltransferasa y sulfobutileter-7-beta-ciclodextrina o 2- hidroxipropil-beta-ciclodextrina y método
CO5570679A2 (es) Compuestos heterociclicos para el uso en el tratamiento de los transtornos de las vias urinarias
BR0013041A (pt) Composto heterociclico e composição farmacêutica para tratar e prevenir doenças mediadas por cgmp-pde, seu uso e método
FI98063B (fi) Menetelmä erytro-(E)-3,5-dihydroksi-7-[3&#39;-(4&#39;&#39;-fluorifenyyli)-1&#39;-(1&#39;&#39;-metyylietyyli)indol-2&#39;-yyli]-hept-6-eenihapon valmistamiseksi
FI871981A0 (fi) Nya dopamin- -hydroxylas-inhibitorer.
AR027335A1 (es) Compuestos de piperidina-4-sulfonamida, proceso de preparacion de los mismos, y composiciones farmaceuticas que los contienen
AR024918A1 (es) Derivados de ciclobuteno, su preparacion y sus usos terapeuticos.
AR002829A1 (es) Procedimiento para preparar compuestos de 3-hidroxipirazol n-sustituidos.
PE20021018A1 (es) DERIVADOS DE ß - CARBOLINA
CO5080752A1 (es) INHIBIDORES DEL FACTOR DE TRANSCRIPCION NF-kB